CZChengcheng Zhang

Chengcheng Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chengcheng Zhang has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Endoscopic treatment and outcome-oriented classification of biliary strictures after liver transplantation: a multicenter retrospective cohort study

    by Zeliang Xu, Danqing Liu, Mingxing Xia, Ji Xuan, Xiubi Yin, Di Jiang, Jingya Kuang, Chengcheng Christine Zhang, Yanjiao Ou, Wei Liu, et al.

    Background: To date, there is no consensus classification of post-liver transplantation biliary strictures (LTBS), particularly for guiding treatment. This study aimed to propose a novel classification system for guiding treatment choice and prognosis prediction. Methods: Patients with biliary stricture (BS) from three centers were analyzed retrospectively. Combined with the latest guidelines, a location-based classification system was developed that included the following categories: extrahepatic BS (type I), perihilar BS (type II), and intrahepatic BS (type III). Stent treatment choices were assessed, and a fully covered self-expandable metal stent (FCMS) with plastic biliary stent (PBS) implantation method for type II was introduced. Treatment characteristics and outcomes among the three types were also analyzed. Results: According to initial successful endoscopic cholangiography, 96 patients were classified into three types: I (43.8%), II (32.3%) and III (24.0%). For type I patients, fewer treatment sessions (P=0.02) and lower costs (P=0.04) were noted for FCMS compared to PBS. Compared to PBS implantation alone, FCMS + PBS had a similar advantage as the type II group. During the follow-up period, 69.0% of type I, 61.3% of type II and 34.7% of type III patients achieved stent-free success, and type III patients demonstrated the worst treatment effects (P=0.03). The stent duration, number of endoscopic procedures increased from type I to type III patients (P=0.04). Conclusions: This location-based classification provides insights for clinical treatment recommendations, offering a typological basis for establishing a standardized treatment protocol for BS after liver transplantation.

  • Open Access

    Machine Learning Model for Predicting Biliary Complications After Liver Transplantation

    by Feng Hu, Yuancheng Li, Hongfei Zeng, Renhua Ju, Di Jiang, Leida Zhang, Jun Li, Xingchao Liu, Guangyi Liu, Chengcheng Zhang

    INTRODUCTION: The risk factors of biliary complications (BCs) after liver transplantation are not comprehensively determined. BCs also vary in times of onset. Machine learning (ML) can reveal regularities based on large-scale data to make predictions and have demonstrated good performance in liver transplantation. However, whether ML can be an efficient tool for BC prediction was not determined. METHODS: Five hundred seventeen patients from 2 centers were enrolled. Patients were randomly divided into training and validation sets at 3:1 ratio. K-fold cross-validation and the synthetic minority oversampling technique were used to debug the models, which were evaluated by receiver operating characteristic curves. SHapley Additive exPlanation values and Sankey diagrams were applied to visualize the results. Seven ML algorithms were administrated to build models for BCs prediction at 3, 6, and 12 months. RESULTS: Among all the models, support vector machine produced the highest area under curve values in predicting BCs (3-month = 0.916; 6-month = 0.892; 12-month = 0.885). According to the analysis of support vector machine, the 3-month risk factors of BCs and corresponding SHapley Additive exPlanation value ranges were donor age (−0.13, 0.21), Model for End-Stage Liver Disease score (−0.15, 0.18), neoplastic disease (−0.14, 0.28), diabetes (−0.12, 0.27), hypertension (−0.13, 0.21), and intraoperative blood transfusion (−0.09, 0.25), whereas 6-month factors were recipient age (−0.14, 0.16), donor body mass index (−0.10, 0.13), recipient body mass index (−0.13, 0.23), and diabetes (−0.12, 0.43). The 12-month risk factors were recipient age (−0.14, 0.19), diabetes (−0.13, 0.25), and basiliximab (−0.16, 0.24). The Sankey diagram enabled clear visualization of the contribution of individual risk factors to the model in different times of BCs onset. DISCUSSION: The ML algorithm was able to identify risk factors of BCs in all postoperative periods and this supplied insights in patient management.


  • Open Access

    A Brief Model Evaluated Outcomes After Liver Transplantation Based on the Matching of Donor Graft and Recipient

    by Yuancheng Li, Xingchao Liu, Chengcheng Zhang, Ran Tao, Bi Pan, Wei Liu, Di Jiang, Feng Hu, Zeliang Xu, Dehong Tan, et al.

    INTRODUCTION: A precise model for predicting outcomes is needed to guide perioperative management. With the development of the liver transplantation (LT) discipline, previous models may become inappropriate or noncomprehensive. Thus, we aimed to develop a novel model integrating variables from donors and recipients for quick assessment of transplant outcomes. METHODS: The risk model was based on Cox regression in a randomly selected derivation cohort and verified in a validation cohort. Perioperative data and overall survival were compared between stratifications grouped by X-tile. Receiver-operating characteristic curve and decision curve analysis were used to compare the models. Violin and raincloud plots were generated to present post-LT complications distributed in different stratifications. RESULTS: Overall, 528 patients receiving LT from 2 centers were included with 2/3 in the derivation cohort and 1/3 in the validation cohort. Cox regression analysis showed that cold ischemia time (CIT) (P = 0.012) and Model for End-Stage Liver Disease (MELD) (P = 0.007) score were predictors of survival. After comparison with the logarithmic models, the primitive algorithms of CIT and MELD were defined as the CIT-MELD Index (CMI). CMI was stratified by X-tile (grade 1 ≤1.06, 1.06 < grade 2 ≤ 1.87, grade 3 >1.87). In both cohorts, CMI performed better in calculating transplant outcomes than the balance of risk score, including perioperative incidents and prevalence of complications. DISCUSSION: The model integrating variables from graft donors and recipients made the prediction more accurate and available. CMI provided new insight into outcome evaluation and risk factor management of LT.

  • Open Access

    Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation

    by Liangjun Zhang, Pingfan Xie, Mingqiao Li, Xiaoxun Zhang, Shuke Fei, Nan Zhao, Ling Li, Qiaoling Xie, Ziqian Xu, Wan Tang, et al.

    Background and Aims: Inflammatory response is crucial for bile acid (BA)-induced cholestatic liver injury, but molecular mechanisms remain to be elucidated. Solute Carrier Family 35 Member C1 (SLC35C1) can transport Guanosine diphosphate-fucose into the Golgi to facilitate protein glycosylation. Its mutation leads to the deficiency of leukocyte adhesion and enhances inflammation in humans. However, little is known about its role in liver diseases. Approach and Results: Hepatic SLC35C1 mRNA transcripts and protein expression were significantly increased in patients with obstructive cholestasis and mouse models of cholestasis. Immunofluorescence revealed that the upregulated SLC35C1 expression mainly occurred in hepatocytes. Liver-specific ablation of Slc35c1 (Slc35c1 cKO) significantly aggravated liver injury in mouse models of cholestasis induced by bile duct ligation and 1% cholic acid–feeding, evidenced by increased liver necrosis, inflammation, fibrosis, and bile ductular proliferation. The Slc35c1 cKO increased hepatic chemokine Ccl2 and Cxcl2 expression and T cell, neutrophil, and F4/80 macrophage infiltration but did not affect the levels of serum and liver BA in mouse models of cholestasis. Liquid chromatography with tandem mass spectrometry analysis revealed that hepatic Slc35c1 deficiency substantially reduced the fucosylation of cell-cell adhesion protein CEACAM1 at N153. Mechanistically, cholestatic levels of conjugated BAs stimulated SLC35C1 expression by activating the STAT3 signaling to facilitate CEACAM1 fucosylation at N153, and deficiency in the fucosylation of CEACAM1 at N135 enhanced the BA-stimulated CCL2 and CXCL2 mRNA expression in primary mouse hepatocytes and Primary Liver Carcinoma/Poliomyelitis Research Foundation/5-ASBT cells. Conclusions: Elevated hepatic SLC35C1 expression attenuates cholestatic liver injury by enhancing CEACAM1 fucosylation to suppress CCL2 and CXCL2 expression and liver inflammation.


  • Open Access

    Residual biliary intraepithelial neoplasia without malignant transformation at resection margin for perihilar cholangiocarcinoma does not require expanded resection: a dual center retrospective study

    by Zeliang Xu, Xiaoyi Fan, Chengcheng Zhang, Yuancheng Li, Di Jiang, Feng Hu, Bi Pan, Yixian Huang, Leida Zhang, Wan Yee Lau, et al.

    Background: Additional resection for invasive cancer at perihilar cholangiocarcinoma (pCCA) resection margins has become a consensus. However, controversy still exists regarding whether additional resection is necessary for residual biliary intraepithelial neoplasia (BilIN). Method: Consecutive patients with pCCA from two hospitals were enrolled. The incidence and pattern of resection margin BilIN were summarized. Prognosis between patients with negative margins (R0) and BilIN margins were analyzed. Cox regression with a forest plot was used to identify independent risk factors associated with overall survival (OS) and recurrence-free survival (RFS). Subgroup analysis was performed based on BilIN features and tumor characteristics. Results: 306 pCCA patients receiving curative resection were included. 255 had R0 margins and 51 had BilIN margins. There was no significant difference in OS (P = 0.264) or RFS (P = 0.149) between the two group. Specifically, 19 patients with BilIN at distal bile ducts and 32 at proximal bile ducts. 42 patients showed low-grade BilIN, and 9 showed high-grade. Further analysis revealed no significant difference in long-term survival between different locations (P = 0.354), or between different grades (P = 0.772). Portal vein invasion, poor differentiation and lymph node metastasis were considered independent risk factors for OS and RFS, while BilIN was not. Subgroup analysis showed no significant difference in long-term survival between the lymph node metastasis subgroup, or between the portal vein invasion subgroup. Conclusion: For pCCA patients underwent curative resection, residual BilIN at resection margin is acceptable. Additional resection is not necessary for such patients to achieve absolute R0 margin.


  • Open Access

    Mechanism and endoscopic‐treatment‐induced evolution of biliary non‐anastomotic stricture after liver transplantation revealed by single‐cell RNA sequencing

    by Zhaoyi Wu, Danqing Liu, Yanjiao Ou, Zeliang Xu, Gang Heng, Wei Liu, Nengsheng Fu, Jingyi Wang, Di Jiang, Lang Gan, et al.

    Background: Biliary complications, especially non‐anastomotic stricture (NAS), are the main complications after liver transplantation. Insufficient sampling and no recognized animal models obstruct the investigation. Thus, the mechanisms and alterations that occur during endoscopic treatment (ET) of NAS remain unclear.Methods: Samples were obtained with endoscopic forceps from the hilar bile ducts of NAS patients receiving continuous biliary stent implantation after diagnosis. Retrospective analysis of multiple studies indicated that the duration of ET for NAS was approximately 1–2 years. Thus, we divided the patients into short‐term treatment (STT) and long‐term treatment (LTT) groups based on durations of less or more than 1 year. Samples were subjected to single‐cell RNA sequencing. Transcriptomic differences between STT and normal groups were defined as the NAS mechanism. Similarly, alterations from STT to LTT groups were regarded as endoscopic‐treatment‐induced evolution.Results: In NAS, inflammation and immune‐related pathways were upregulated in different cell types, with nonimmune cells showing hypoxia pathway upregulation and immune cells showing ATP metabolism pathway upregulation, indicating heterogeneity. We confirmed a reduction in bile acid metabolism‐related SPP1+ epithelial cells in NAS. Increases in proinflammatory and profibrotic fibroblast subclusters indicated fibrotic progression in NAS. Furthermore, immune disorders in NAS were exacerbated by an increase in plasma cells and dysfunction of NK and NKT cells. ET downregulated multicellular immune and inflammatory responses and restored epithelial and endothelial cell proportions.Conclusions: This study reveals the pathophysiological and genetic mechanisms and evolution of NAS induced by ET, thereby providing preventive and therapeutic insights into NAS.Highlights: For the first time, single‐cell transcriptome sequencing was performed on the bile ducts of patients with biliary complications. scRNA‐seq analysis revealed distinct changes in the proportion and phenotype of multiple cell types during Nonanastomotic stricture (NAS) and endoscopic treatment. A reduction in bile acid metabolism‐related SPP1+ epithelial cells and VEGFA+ endothelial cells, along with explosive infiltration of plasma cells and dysfunction of T and NK cells in NAS patients. SPP1+ macrophages and BST2+ T cells might serve as a surrogate marker for predicting endoscopic treatment.


  • RUNX3 improves CAR-T cell phenotype and reduces cytokine release while maintaining CAR-T function

    by Xiuxiu Zhu, Wuling Li, Jiadong Gao, Junjie Shen, Yanmin Xu, Chengcheng Zhang, Cheng Qian

    CAR-T therapy has shown successful in the treatment of certain types of hematological malignancy, while the efficacy of CAR-T cell in treating solid tumors has been limited due to the exhaustion of CAR-T caused by the tumor microenvironment in solid tumors. Therefore, improving the exhaustion of CAR-T cell is one of the inspiring strategies for CAR-T treatment of solid tumors. As an important regulator in T cell immunity, the transcription factor RUNX3 not only negatively regulates the terminal differentiation T-bet gene, reducing the ultimate differentiation of T cells, but also increases the residency of T cells in non-lymphoid tissues and tumors. By overexpressing RUNX3 in CAR-T cells, we found that increasing the expression of RUNX3 maintained the low differentiation of CAR-T cells, further improving the exhaustion of CAR-T cells during antigen stimulation. In vitro, we found that RUNX3 could reduce the release of cytokines while maintaining CAR-T cells function. In re-challenge experiments, CAR-T cells overexpressing RUNX3 (Runx3-OE CAR-T) were safer than conventional CAR-T cells, while RUNX3 could also maintain the anti-tumor efficacy of CAR-T cells in vivo. Collectively, we found that Runx3-OE CAR-T cells can improve CAR-T phenotype and reduce cytokines release while maintaining CAR-T cells function, which may improve the safety of CAR-T therapy in clinical trials.


  • Open Access

    Runt-related transcription factor-1 ameliorates bile acid–induced hepatic inflammation in cholestasis through JAK/STAT3 signaling

    by Liangjun Zhang, Qiong Pan, Lu Zhang, Haihan Xia, Junwei Liao, Xiaoxun Zhang, Nan Zhao, Qiaoling Xie, Min Liao, Ya Tan, et al.

    Background and Aims: Bile acids trigger a hepatic inflammatory response, causing cholestatic liver injury. Runt-related transcription factor-1 (RUNX1), primarily known as a master modulator in hematopoiesis, plays a pivotal role in mediating inflammatory responses. However, RUNX1 in hepatocytes is poorly characterized, and its role in cholestasis is unclear. Herein, we aimed to investigate the role of hepatic RUNX1 and its underlying mechanisms in cholestasis. Approach and Results: Hepatic expression of RUNX1 was examined in cholestatic patients and mouse models. Mice with liver-specific ablation of Runx1 were generated. Bile duct ligation and 1% cholic acid diet were used to induce cholestasis in mice. Primary mouse hepatocytes and the human hepatoma PLC/RPF/5-ASBT cell line were used for mechanistic studies. Hepatic RUNX1 mRNA and protein levels were markedly increased in cholestatic patients and mice. Liver-specific deletion of Runx1 aggravated inflammation and liver injury in cholestatic mice induced by bile duct ligation or 1% cholic acid feeding. Mechanistic studies indicated that elevated bile acids stimulated RUNX1 expression by activating the RUNX1-P2 promoter through JAK/STAT3 signaling. Increased RUNX1 is directly bound to the promotor region of inflammatory chemokines, including CCL2 and CXCL2, and transcriptionally repressed their expression in hepatocytes, leading to attenuation of liver inflammatory response. Blocking the JAK signaling or STAT3 phosphorylation completely abolished RUNX1 repression of bile acid–induced CCL2 and CXCL2 in hepatocytes. Conclusions: This study has gained initial evidence establishing the functional role of hepatocyte RUNX1 in alleviating liver inflammation during cholestasis through JAK/STAT3 signaling. Modulating hepatic RUNX1 activity could be a new therapeutic target for cholestasis.


  • Open Access

    Vascular invasion and lymph node metastasis mediate the effect of CA242 on prognosis in hilar cholangiocarcinoma patients after radical resection

    by Gang Heng, Benqi Huang, Yanbing Shen, Dan Wang, Zhen Lan, Yuxuan Yao, Jianxin Zhang, Jiankun Jia, Chengcheng Zhang

    Background: Carbohydrate antigen 242 has been clinically used as a diagnostic biomarker for pancreatic cancer. However, the prognostic role of CA242 in hilar cholangiocarcinoma (HCCA) has not been identified. Also, it remains unclear to what extents the vascular invasion and lymph node metastasis mediate the effect of serum CA242 on prognosis.Objective: This study aimed to investigate whether vascular invasion and lymph node metastasis mediate the relationship between CA242 levels and clinical prognosis in HCCA patients after radical resection.Methods: Data of 234 HCCA patients who accepted radical resection from March 2008 to December 2014 were analyzed. Vascular invasion and lymph node metastasis were assessed by postoperative pathological examinations. Mediation analysis was performed to study the potential causal relationship between CA242 and overall survival (OS) and relapse-free survival (RFS). Survival analysis was performed using the Kaplan-Meier method.Results: Among 234 HCCA patients, 104 patients (44.4%) with normal CA242 levels (≤ 20 IU/ml) had significantly better OS (p=0.004) and RFS (p=0.001) than those 130 patients (55.6%) with elevated CA242 levels (>20 IU/ml). The logistic analysis showed that elevated CA242 was an independent risk factor for vascular invasion (p=0.006) and lymph nodes metastasis (p=0.040). The causal mediation analysis indicated that the vascular invasion (p=0.012 for OS; p=0.036 for RFS) and lymph nodes metastasis (p=0.024 for OS; p=0.014 for RFS) played significant roles in mediating the effect of serum CA242 on OS and RFS.Conclusion: Serum elevated CA242 could be a novel marker for prognosis prediction in HCCA patients. Vascular invasion and lymph node metastasis mediated the relationship between CA242 and clinical prognosis.


  • Gastroduodenal artery disconnection during liver transplantation decreases non-anastomotic stricture incidence

    by Bi Pan, Wei Liu, Yan-Jiao Ou, Yan-Qi Zhang, Di Jiang, Yuan-Cheng Li, Zhi-Yu Chen, Lei-Da Zhang, Cheng-Cheng Zhang